Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as "evergreening". The analysis focuses on two of these strategies, namel...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Nomos Verlagsgesellschaft mbH & Co. KG
2014
|
| Series: | Munich Intellectual Property Law Center - MIPLC
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_55772 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2014 xx |||||o ||| 0|eng d | ||
| 020 | |a /dx.doi.org/10.5771/9783845251288 | ||
| 020 | |a 9783845251288 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a http://dx.doi.org/10.5771/9783845251288 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 100 | 1 | |a Donghi, Monica |4 auth | |
| 245 | 1 | 0 | |a Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| 260 | |b Nomos Verlagsgesellschaft mbH & Co. KG |c 2014 | ||
| 300 | |a 1 electronic resource (84 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Munich Intellectual Property Law Center - MIPLC | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as "evergreening". The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two "blockbuster" drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 653 | |a Markenrecht | ||
| 653 | |a Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht | ||
| 653 | |a Gewerblicher Rechtsschutz | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://www.nomos-elibrary.de/10.5771/9783845251288 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/55772 |7 0 |z DOAB: description of the publication |